Proximity labelling and single-particle tracking demonstrated that effectors in bacteria bind to mobile injectisome components.
List view / Grid view
Researchers highlight the need for a more nuanced diagnostic approach, examining whether nonglycemic markers could refine risk stratification.
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
A new strategy enables researchers to be more precise in the control of gene expression of a therapeutic protein.
For diseases mediated by NLRP3, AIM2, NLRC4, and Pyrin, understanding inflammasome biology could identify therapeutic targets.
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
One gene involved in the production of iron-sulphur clusters may be crucial for the persistence of Mycobacterium tuberculosis.
The new antibodies can neutralise certain H1 and H3 strains with or without the 133a insertion, which could lead to improved vaccines.
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
Understanding the involvement of Nod1 in the development of blood stem cells could greatly improve blood disorder treatments.
A 2D neuromuscular junction model enables high-throughput screening to discover new treatments for neuromuscular diseases.
A new finding that pathological alpha-synuclein causes cells to increase protein synthesis suggests new targets for treating PD.
New software can make protein molecules that bind with high affinity and specificity to many biomarkers, including human hormones.
New understanding of the communication system between pathogens and host cells provides a way to avoid antimicrobial resistance.
In vitro and in vivo experiments highlight the advantages of a new targeted spectroscopy system for many eye diseases.